Study limitation: Brepocitinib is described as 'first-in-class' and phase 3; regulatory approval status as of the publication date is not stated in the paper | ReachRx
Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis
Study limitation reported by the research below: “Brepocitinib is described as 'first-in-class' and phase 3; regulatory approval status as of the publication date is not stated in the paper.”
